Amarillo researchers identify promising compounds to treat neurodegenerative diseases

Abraham Al-Ahmad and Paul Trippier

Abraham Al-Ahmad and Paul Trippier

A study published in the November issue of the Journal of Medicinal Chemistry, the nation’s leading medicinal chemistry journal, describes new compounds designed and synthetized in the lab of Paul Trippier, Ph.D., that show the effects of protecting human neurons in a dish from a form of cell death common in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.

Trippier is an assistant professor for the Department of Pharmaceutical Sciences at the Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy in Amarillo. He is collaborating with the lab of Abraham Al-Ahmad, an assistant professor in the same TTUHSC School of Pharmacy department. 

Trippier said the TTUHSC research team grew functional human neurons from stem cells and then treated them with the synthesized compounds. When cell death was induced, many more neurons that had been treated with the new compounds survived than did those that were not treated. 

“These compounds are in the early stages of drug discovery, but they show promise for the treatment of many different types of neurodegenerative disease,” Trippier said. “The advantage to this study is the use of stem cell-derived functional human neurons. Many studies have identified compounds that can protect either neuron-like cells or mouse neurons, but they rarely carry forward to show effect in humans.”

As the compounds developed in his and Al-Alamad’s labs already show effect in human neurons, Trippier said they are much more likely to be effective in patients, albeit in the distant future.

Related Stories

TTUHSC’s Graduate School of Biomedical Sciences Hosts Student Research Week

The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.

TTUHSC Researcher Receives NIH Grant to Study Vulnerabilities in Specific Cancer Types

The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.

The Hype Around Artificial Intelligence

Richard Greenhill, DHA, FISQua, FACHE, discusses the hype and reality surrounding AI in healthcare.

Recent Stories

Education

TTUHSC Class of 2022 Honored at Commencement Ceremonies

The Texas Tech University Health Sciences Center (TTUHSC) recently hosted traditional commencement ceremonies for its 1,595-member Class of 2022.

Education

TTUHSC Announces the Julia Jones Matthews School of Population and Public Health

The school, which is the sixth at the university, aims to train future health care leaders in population and public health.

Education

TTUHSC Jerry H. Hodge School of Pharmacy Class of 2022 Honored at Commencement Ceremony

The TTUHSC Jerry H. Hodge School of Pharmacy celebrated the Class of 2022 May 21 with its annual commencement ceremony.